Nanobiotix S.A.
Business
Nanobiotix S.A. is a late-stage clinical biotechnology company that develops physics-based, nanoparticle therapies to improve cancer and CNS treatment outcomes. Its main product candidates and platforms include NBTXR3 (a radiotherapy-activated hafnium oxide nanoparticle radioenhancer), Curadigm (nanoprimer technology to improve therapeutic index), and Oocuity (nanomaterials for CNS disorders). The company operates through clinical development, manufacturing partnerships and strategic licensing/collaboration arrangements. It advances global clinical programs and distributes through clinical centers and commercial partners across the United States, Europe, Asia and other international markets.
Summary from filing dated 2025-04-02
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-24.00M |
| Total assets | $67.76M |
| Total liabilities | $152.24M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Nanobiotix S.A.'s CIK number?
Nanobiotix S.A.'s SEC CIK number is 0001760854 (1760854). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Nanobiotix S.A.'s SEC filings?
All of Nanobiotix S.A.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.